video

Engineering better CAR T cells with Professor Ann Ager, Cardiff University

Posted: 27 October 2021 | | No comments yet

Watch this exclusive interview with Professor Ann Ager, Cardiff University, to discover how CAR T cells could be targeted against solid tumours.

Sign up for Drug Target Review‘s Cell & Gene Therapy Advancements Online Summit for FREE here

Dr Ann Ager, Professor of Cellular Immunity and Immunotherapy in the School of Medicine at Cardiff University, UK. Ann discusses CAR T cells in this exclusive interview with Drug Target Review‘s Deputy Editor, Victoria Rees. Ager outlines why CAR T cells have shown limited success against solid tumours and recent research into how this class of cell therapy could be engineered to tackle a wider range of cancers.

“The major breakthrough in the last 10 years or so is the realisation that the immune system is actually in battle with the cancer,” says Ager. “We have known for years that we can find immune cells inside cancers, but we have not understood what they might be doing there. The progress has been understanding that we can harness the patient’s own immune system to attack cancer.” 

To hear Professor Ann Ager expand on her research and listen to other experts in the world of immuno-oncology discuss how to improve CAR T cells, sign up for Drug Target Review‘s Cell & Gene Therapy Advancements Online Summit for FREE here: https://bit.ly/3Bo44jo 

Send this to a friend